Small Molecule Innovator CDMO Market Size, Share, Opportunities, And Trends By Product (Small Molecule API, Small Molecule Drug Product), By Customer Type (Preclinical, Clinical, Commercial), By Therapeutic Area (Cardiovascular Disease, Oncology, Respiratory Disorders, Neurology, Metabolic Disorders, Infectious Disease, Others), And By Geography - Forecasts From 2024 To 2029

The small molecule innovator CDMO market is projected to grow at a CAGR of 7.74% during the forecast period thereby reaching a market size of US$86.247 billion in 2029 from an initial value of US$51.165 billion in 2022.

The increasing aging population globally is creating demand for healthcare services tailored to the needs of elderly individuals. Additionally, the prevalence of chronic ailments has seen a notable uptick, further fueling the demand for innovative small-molecule drugs.

Moreover, governments are increasingly allocating resources to support the development and manufacturing of pharmaceuticals, including small-molecule drugs. This is in response to the growing healthcare needs of their populations. For instance, the establishment of the pharmaceutical investment company (Lifera) by the Public Investment Fund (PIF) of Saudi Arabia on June 2023.

Lifera is positioned as a commercial-scale CDMO with a focus on manufacturing life-saving and essential pharmaceutical products. This includes a diverse range of medical solutions such as insulins, vaccines, plasma therapeutics, monoclonal antibodies, cell and gene therapies, and innovative small molecules. The creation of such entities demonstrates a commitment to fostering the growth of the pharmaceutical and addresses the challenges posed by the surge in chronic diseases and the aging demographic.

Increasing cases of chronic ailments drive the market.

Globally, the increasing incidence of various health conditions such as cancer and diabetes has led to a heightened demand for small-molecule drugs, which are commonly employed in the treatment of these ailments. The available data indicates a substantial rise in the prevalence of diseases worldwide.

In the United States, according to data from the American Cancer Society, the projected number of new cancer cases in 2022 is approximately 983,160 for males and 934,870 for females. These statistics serve as a stark reminder of the profound impact of cancer as a widespread health issue. The prevalence of cancer underscores the critical importance of sustained and comprehensive efforts in prevention, early detection, diagnosis, and treatment within the healthcare sector. It emphasizes the ongoing imperative for healthcare professionals, researchers, policymakers, and communities to collaborate effectively in combating this pervasive disease.

Furthermore, these figures reinforce the urgency of advancing medical research, implementing evidence-based interventions, and enhancing access to quality care for individuals affected by cancer across all segments of society. Ultimately, addressing the multifaceted challenges posed by cancer remains a paramount priority in the quest to improve public health outcomes and alleviate the burden of this disease on individuals and communities alike.

Further, these statistics underscore the pressing need for pharmaceutical solutions, particularly in the realm of small-molecule drugs. The demand for these medicines is driven by their potential to reduce costs, provide access to specialized expertise, and enhance overall speed and efficiency in drug development and manufacturing processes. As the global health landscape evolves, the pharmaceutical industry faces the need to meet the growing demand for effective treatments, emphasizing the importance of such services and healthcare solutions.

Additionally, the growing elderly demographic is contributing to an increased need for novel healthcare services, specifically in the realm of small molecule innovation through Contract Development and Manufacturing Organizations (CDMOs). In the United States, the population aged 65 and older has undergone significant expansion, totaling 55.8 million individuals or 16.8% of the overall population in 2020. This demographic shift signals a clear trend toward an aging society.  As people advance in age, there arises a growing demand for healthcare solutions that is meet the unique needs of the elderly population.

Increasing need for small molecule medications further propels the market growth.

The demand for small molecule drugs is witnessing a significant increase due to their proven effectiveness in treating a diverse array of diseases and medical conditions. Pharmaceutical companies are increasingly drawn to small molecule medications because of their straightforward manufacturing processes and lower production costs. Consequently, there has been a notable rise in the requirement for small molecule innovator Contract Development and Manufacturing Organization (CDMO) services. These specialized services are highly sought after for their expertise in both the development and production of small molecule drugs, catering to the escalating demand from pharmaceutical firms seeking efficient and cost-effective solutions. The growing reliance on small molecule drugs highlights the critical role of CDMOs in the pharmaceutical industry, fostering innovation and enabling the widespread delivery of vital therapies to patients across the globe.

The China small molecule innovator CDMO market is predicted to expand steadily. 

The rise in clinical trial activity with a significant increase in contract development & and manufacturing organizations (CDMOs) offering end-to-end services in the country is expected to boost the market growth. In addition to this, the high disease burden in China provides further impetus to meet the growing demand for drug development and manufacturing processes. Furthermore, China is a highly preferred country for conducting clinical trials owing to its large pool of local experts and regulatory actions by clinical trial bodies. For instance- NMPA's Center for Drug Evaluation in China takes initiatives to improve the quality of clinical trial studies at low cost, supporting the development of CDMO services.

As per the estimates from WHO, the aging population in China is expected to grow multifold in upcoming years attributed to longer life expectancy and declining fertility rates. By the year 2040, it is expected to reach 402 million people from 254 million people in 2019. This reflects the increasing demand for drug discovery and development, promoting the growth of the small molecule innovator CDMO market till the forecast period.

Market Key Developments:

• In June 2023, Porton Pharma Solutions unveiled a state-of-the-art Small Molecule Platform in Shanghai, which significantly enhanced its CDMO (Contract Development and Manufacturing Organization) services. Through their Small Molecule Platform, they provided a comprehensive solution, merging their knowledge, state-of-the-art infrastructure, and advanced technologies to expedite and simplify the development of therapeutics based on small molecules.
• In January 2023, Lonza completed the expansion of its Solid Form Services Facility in Bend, USA. This expanded facility includes dedicated laboratory space designed to support biotech and midsize pharmaceutical companies in their early-stage compound development. It offers comprehensive support for solid form screening, characterization of small molecule active pharmaceutical ingredients (APIs), and early-stage crystallization process development.
• In September 2022, WuXi STA, a subsidiary of WuXi AppTec, announced the opening of its new sterile lipid nanoparticle formulation facility. The integrated drug product platform CRDMO will offer various services. These include such as pre-formulation, formulation development, solid-state development, and clinical to commercial drug product manufacturing with a wide spectrum of drug delivery technologies.

Small Molecule Innovator CDMO Market Scope:

 

Report Metric	Details
Market Size Value in 2022	US$51.165 billion
Market Size Value in 2029	US$86.247 billion
Growth Rate	CAGR of 7.74% from 2022 to 2029
Study Period	2019 to 2029
Historical Data	2019 to 2022
Base Year	2023
Forecast Period	2024 – 2029
Forecast Unit (Value)	USD Billion
Segments Covered	Product Customer Type Therapeutic Area Geography
Companies Covered	CatSci Ltd. Eurofins Scientific Lonza Sai Life Sciences Ardena
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Product 
  • Small Molecule API
  • Small Molecule Drug Product
• By Customer Type
  • Preclinical
  • Clinical
  • Commercial
• By Therapeutic Area
  • Cardiovascular Disease
  • Oncology
  • Respiratory Disorders
  • Neurology
  • Metabolic Disorders
  • Infectious Disease
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • UK
    • France
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • Taiwan
    • Indonesia
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits for the stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. SMALL MOLECULE INNOVATOR CDMO MARKET, BY PRODUCT

5.1. Introduction

5.2. Small Molecule API

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Small Molecule Drug Product

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

6. SMALL MOLECULE INNOVATOR CDMO MARKET, BY CUSTOMER TYPE

6.1. Introduction

6.2. Preclinical

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Clinical

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

6.4. Commercial

6.4.1. Market Trends and Opportunities

6.4.2. Growth Prospects

6.4.3. Geographic Lucrativeness

7. SMALL MOLECULE INNOVATOR CDMO MARKET, BY THERAPEUTIC AREA

7.1. Introduction

7.2. Cardiovascular Disease

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.2.3. Geographic Lucrativeness

7.3. Oncology

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

7.3.3. Geographic Lucrativeness

7.4. Respiratory Disorders

7.4.1. Market Trends and Opportunities

7.4.2. Growth Prospects

7.4.3. Geographic Lucrativeness

7.5. Neurology 

7.5.1. Market Trends and Opportunities

7.5.2. Growth Prospects

7.5.3. Geographic Lucrativeness

7.6. Metabolic Disorders

7.6.1. Market Trends and Opportunities

7.6.2. Growth Prospects

7.6.3. Geographic Lucrativeness

7.7. Infectious Diseases

7.7.1. Market Trends and Opportunities

7.7.2. Growth Prospects

7.7.3. Geographic Lucrativeness

7.8. Others

7.8.1. Market Trends and Opportunities

7.8.2. Growth Prospects

7.8.3. Geographic Lucrativeness

8. SMALL MOLECULE INNOVATOR CDMO MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Product 

8.2.2. By Customer Type

8.2.3. By Therapeutic Area

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Trends and Opportunities

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Trends and Opportunities

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Trends and Opportunities

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Product 

8.3.2. By Customer Type

8.3.3. By Therapeutic Area

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Trends and Opportunities

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Trends and Opportunities

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Trends and Opportunities

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Product 

8.4.2. By Customer Type

8.4.3. By Therapeutic Area

8.4.4. By Country

8.4.4.1. Germany

8.4.4.1.1. Market Trends and Opportunities

8.4.4.1.2. Growth Prospects

8.4.4.2. United Kingdom

8.4.4.2.1. Market Trends and Opportunities

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Trends and Opportunities

8.4.4.3.2. Growth Prospects

8.4.4.4. Others

8.4.4.4.1. Market Trends and Opportunities

8.4.4.4.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Product 

8.5.2. By Customer Type

8.5.3. By Therapeutic Area

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Trends and Opportunities

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Trends and Opportunities

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Trends and Opportunities

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Product 

8.6.2. By Customer Type

8.6.3. By Therapeutic Area

8.6.4. By Country

8.6.4.1. Japan 

8.6.4.1.1. Market Trends and Opportunities

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Trends and Opportunities

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Trends and Opportunities

8.6.4.3.2. Growth Prospects

8.6.4.4. Thailand

8.6.4.4.1. Market Trends and Opportunities

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Trends and Opportunities

8.6.4.5.2. Growth Prospects

8.6.4.6. Indonesia

8.6.4.6.1. Market Trends and Opportunities

8.6.4.6.2. Growth Prospects

8.6.4.7. Others

8.6.4.7.1. Market Trends and Opportunities

8.6.4.7.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. CatSci Ltd.

10.2. Eurofins Scientific

10.3. Lonza

10.4. Sai Life Sciences

10.5. Ardena

10.6. Recipharm

10.7. Cambrex

10.8. Merck Millipore

10.9. Catalent

10.10. AGC Pharma Chemicals Europe 

CatSci Ltd.

Eurofins Scientific

Lonza

Sai Life Sciences

Ardena

Recipharm

Cambrex

Merck Millipore

Catalent

AGC Pharma Chemicals Europe